PLEKHF2 Inhibitors
Pleckstrin homology domain-containing family F member 2 (PLEKHF2) inhibitors constitute a class of chemical compounds that are designed to modulate or suppress the function of PLEKHF2, a protein that plays crucial roles in early endosome fusion and the regulation of cellular apoptosis sensitivity. By targeting this protein, these inhibitors aim to manipulate essential cellular processes, potentially influencing various cellular outcomes.
The compounds classified under this category display a diverse range of mechanisms. Some are known to inhibit pathways that might be intricately linked with PLEKHF2's function. For instance, compounds that inhibit PI3K might indirectly disrupt the protein's role in early endosome fusion, given the known association of PI3K signaling with endosome processes. Others target enzymes and pathways linked to apoptosis, which could, in turn, affect the protein's role in modulating apoptosis sensitivity. The breadth of this category is indicative of the complex network of cellular pathways in which PLEKHF2 might be involved, underscoring the importance of comprehensive research in understanding the exact mechanisms and implications of these inhibitors.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a known PI3K inhibitor. Given that PI3K signaling is associated with endosome fusion, inhibiting PI3K might indirectly affect PLEKHF2's role in early endosome fusion. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, and could thus influence PLEKHF2's involvement in endosome fusion by disrupting this pathway. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
This compound is an inhibitor of class III PI3K, which may potentially alter PLEKHF2's function in endosome fusion. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 inhibits vacuolar H+-ATPases, potentially influencing PLEKHF2's role in endosomal processes. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
As a beta-blocker, propranolol might alter cellular apoptosis processes, indirectly affecting PLEKHF2's enhancement of apoptosis sensitivity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein inhibits tyrosine kinases, potentially influencing cellular pathways that involve PLEKHF2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits the MAPK pathway, which may indirectly influence PLEKHF2's functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This compound inhibits the JNK signaling pathway, potentially altering PLEKHF2's role in cellular apoptosis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
As a p38 MAPK inhibitor, SB203580 might influence pathways linked with PLEKHF2's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By inhibiting mTOR, rapamycin might indirectly affect PLEKHF2's role in cellular processes. | ||||||